How one father's loss turned into gain for cystic fibrosis patients and Vertex Pharmaceuticals ($VRTX): After the death of his son, Boston businessman Joe O'Donnell spent years raising $250 million for the Cystic Fibrosis Foundation, which backed Vertex's development of the groundbreaking treatment Kalydeco. Report